Retatrutide: The Triple Receptor Agonist Peptide Explained
By UK Peptide Lab Research Team•10 February 2025•7 min read
What is Retatrutide?
Retatrutide is a synthetic peptide and triple receptor agonist that simultaneously targets three receptors — the glucose-dependent insulinotropic polypeptide receptor (GIPR), the glucagon-like peptide-1 receptor (GLP-1R), and the glucagon receptor (GCGR). Developed by Eli Lilly, it represents a significant advancement in incretin-based research compared to earlier dual agonists such as Tirzepatide or single agonists such as Semaglutide. Its unique triple mechanism has made it one of the most actively researched peptides in metabolic science in recent years.
Molecular Mechanism
Retatrutide operates through simultaneous agonism at three distinct receptor pathways. GLP-1 receptor activation is associated with insulin secretion modulation and appetite signalling research. GIPR activation influences insulin and glucagon secretion in glucose-dependent contexts. Glucagon receptor agonism affects hepatic glucose output and energy expenditure pathways. The combination of all three mechanisms in a single peptide makes Retatrutide a uniquely powerful research tool for studying metabolic regulation, energy homeostasis, and receptor crosstalk in laboratory models.
How Retatrutide Differs From Semaglutide and Tirzepatide
Semaglutide is a single GLP-1 receptor agonist. Tirzepatide is a dual GIP/GLP-1 agonist. Retatrutide adds glucagon receptor agonism on top of both, creating a triple mechanism that research suggests produces more pronounced effects on energy expenditure pathways than either predecessor. Phase 2 clinical trial data published in the New England Journal of Medicine in 2023 demonstrated significant findings in metabolic outcomes, generating substantial interest in Retatrutide as a research compound.
Current Research Status
Retatrutide is currently in Phase 3 clinical trials as of 2024. It is not approved for human use by any regulatory body including the MHRA or FDA. All research involving Retatrutide must be conducted in controlled laboratory settings following appropriate ethical and safety guidelines.
Laboratory Handling and Reconstitution
Retatrutide is supplied as a lyophilised powder. Store at -20°C prior to reconstitution. Reconstitute with bacteriostatic water by slowly injecting the diluent down the side of the vial and gently swirling — never shake. Once reconstituted store at +4°C and use within 4 weeks. Handle under sterile conditions throughout.
Sourcing Research Peptides in the UK
UK Peptide Lab supplies research-grade peptides as lyophilised powder sourced from GMP certified manufacturers, with full batch documentation. Available for purchase in the UK with fast Royal Mail tracked delivery. For laboratory and in-vitro research use only. Browse all products.
Related Products
Disclaimer: This article is for research and educational purposes only. All information provided is not intended as medical advice. UK Peptide Lab products are not for human consumption and are sold strictly for laboratory research use only.